BioMed Research International

Propelling Healthcare with Advanced Therapy: The Future of Medicine


Publishing date
01 Oct 2022
Status
Closed
Submission deadline
03 Jun 2022

Lead Editor

1Chinese PLA General Hospital, Beijing, China

2Fourth Military Medical University, Beijing, China

3Institute of Health Service and Transfusion Medicine, Beijing, China

4Center for Regenerative Medicine and Stem Cell Research at USC, Los Angeles, China

5Chinese PLA General Hospital, Wuhan, China

6Florida State University, Tallahassee, USA

This issue is now closed for submissions.

Propelling Healthcare with Advanced Therapy: The Future of Medicine

This issue is now closed for submissions.

Description

Advanced therapies, particularly those under the Regenerative Medicine and Advanced Therapy (RMAT) designation within the U.S. or as part of the Advanced Therapy Medicinal Products (ATMP) in many other regions, have shown promising clinical efficacy and are changing the paradigm for treating diseases and injuries. Recent advances in biomedicine are opening the door to new approaches, and treatment and prevention are being transformed by novel medicines based on genetic engineering, regenerative medicine, innovative cell-based therapies and tissue-engineered products, and combinations of a medical device with embedded cell or tissue components. Advanced therapies are now experiencing rapid progress fueled by scientific and technology advancements, providing new innovative opportunities for the treatment of diseases and injuries, especially for many of the world's most pressing diseases beyond the reach of traditional approaches.

Clinical translation and patient access to this broad class of therapeutics requires better defined and characterized products and more robust, reliable, and cost-effective manufacturing processes. These advanced therapy medicinal techniques can potentially restore diseased and injured tissues and whole organs. Since the inception of the field several decades ago, several regenerative medicine advanced therapies, including those designed for wound healing and orthopedics applications, have received Food and Drug Administration (FDA) approval and are now commercially available. There are an estimated 450 companies across the globe working on the development of gene therapies and more than 1,000 clinical trials underway worldwide, and some 20–30 new advanced therapy medicinal products filings are expected in Europe annually over the next 5 years. They hold one of the keys to making a reality of genuine revolution medicine. However, clinical translation from bench to bedside and patient access to this broad class of therapeutics requires better defined and characterized products and more robust, reliable, and cost-effective manufacturing processes.

The aim of this Special Issue is to bring together original research and review articles discussing advanced therapies, which sets out the achievements to date with this new group of products, the principal challenges to their development, some possible immediate ways ahead, and the longer-term options for integrating advanced therapies into more impactful healthcare systems that capitalise on the opportunities of personalised medicine and globally harmonized practices and standards.

Potential topics include but are not limited to the following:

  • Regenerative medicine
  • Gene therapy
  • Immunotherapy
  • Gene-editing
  • Stem cell therapy
  • Personalised medicine
  • Tissue engineering
  • Biomaterials
  • Precision medicine
  • Artificial intelligence in medicine
  • Engineering / synthetic biology
  • Healthcare policy

Articles

  • Special Issue
  • - Volume 2024
  • - Article ID 9852141
  • - Retraction

Retracted: Cell-in-Cell: From Cell Biology to Translational Medicine

BioMed Research International
  • Special Issue
  • - Volume 2024
  • - Article ID 9825156
  • - Retraction

Retracted: Using Haemocoagulase Agkistrodon in Patients Undergoing Transurethral Plasmakinetic Resection of the Prostate: A Pilot, Real-World, and Propensity Score-Matched Study

BioMed Research International
  • Special Issue
  • - Volume 2024
  • - Article ID 9753837
  • - Retraction

Retracted: A Novel Missense Mutation of Arginine Vasopressin Receptor 2 in a Chinese Family with Congenital Nephrogenic Diabetes Insipidus: X-Chromosome Inactivation in Female CNDI Patients with Heterozygote 814A>G Mutation

BioMed Research International
  • Special Issue
  • - Volume 2022
  • - Article ID 8094351
  • - Review Article

Advances in Cuffless Continuous Blood Pressure Monitoring Technology Based on PPG Signals

Caijie Qin | Xiaohua Wang | ... | Xibo Ma
  • Special Issue
  • - Volume 2022
  • - Article ID 7608521
  • - Review Article

[Retracted] Cell-in-Cell: From Cell Biology to Translational Medicine

Qiao Chen | Xiaoning Wang | Meifang He
  • Special Issue
  • - Volume 2022
  • - Article ID 7073158
  • - Research Article

[Retracted] A Novel Missense Mutation of Arginine Vasopressin Receptor 2 in a Chinese Family with Congenital Nephrogenic Diabetes Insipidus: X-Chromosome Inactivation in Female CNDI Patients with Heterozygote 814A>G Mutation

Li Zang | Yuping Gong | ... | Yiming Mu
  • Special Issue
  • - Volume 2022
  • - Article ID 9200854
  • - Research Article

[Retracted] Using Haemocoagulase Agkistrodon in Patients Undergoing Transurethral Plasmakinetic Resection of the Prostate: A Pilot, Real-World, and Propensity Score-Matched Study

Cong Zhu | Lan Yang | ... | Xian-Tao Zeng
  • Special Issue
  • - Volume 2022
  • - Article ID 9346939
  • - Review Article

Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends

Amaan Javed | Saurab Karki | ... | Sara Saxena
BioMed Research International
 Journal metrics
See full report
Acceptance rate8%
Submission to final decision110 days
Acceptance to publication24 days
CiteScore5.300
Journal Citation Indicator-
Impact Factor-
 Submit Check your manuscript for errors before submitting

Article of the Year Award: Impactful research contributions of 2022, as selected by our Chief Editors. Discover the winning articles.